In this segment fromĀ Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look into Sanofi (NYSE:SNY) after its earnings report to discuss some of the biggest upcoming drugs in the company's pipeline.

As the company's flagship product, its insulin Lantus, nears the patent cliff, the guys look at the company's Lantus replacement, U300, ahead of its upcoming filing. They also look at Sanofi's PCSK9 drug alirocumab, which would compete directly with Amgen's (NASDAQ:AMGN) and Pfizer's (NYSE:PFE) offerings in this space, and which should be releasing phase 3 data in late summer or early fall.

David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.